University of California San Francisco

Michael Ou
Michael Ou, MD

Resident Research Fellow
General Surgery

[email protected]

Education

Institution Degree Dept or School End Date
Johns Hopkins School of Medicine M.D. 05/2022
Johns Hopkins University B.S. Neuroscience 05/2016

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 19
  1. PASC in Solid Organ Transplant Recipients With Self-reported SARS-CoV-2 Infection.
    Alasfar S, Chiang TP, Snyder AJ, Ou MT, Boyarsky BJ, Abedon AT, Alejo JL, Cook S, Cochran W, Brigham E, Parker AM, Garonzik-Wang J, Massie AB, Brennan DC, Vannorsdall T, Segev DL, Avery RK| | PubMed
  2. Low-volume hospitals are not associated with inferior outcomes after thoracic endovascular aortic repair.
    Alhajri N, Yin K, Locham S, Ou M, Malas MB| | PubMed
  3. SARS-CoV-2 Messenger RNA Vaccine Immunogenicity in Solid Organ Transplant Recipients With Prior COVID-19.
    Boyarsky BJ, Barbur I, Chiang TP, Ou MT, Greenberg RS, Teles AT, Krach MR, Lรณpez JI, Garonzik-Wang JM, Avery RK, Massie AB, Segev DL, Werbel WA| | PubMed
  4. Antibody Kinetics and Durability in SARS-CoV-2 mRNA Vaccinated Solid Organ Transplant Recipients.
    Boyarsky BJ, Chiang TP, Teles AT, Greenberg RS, Krach MR, Ou MT, Massie AB, Tobian AAR, Garonzik-Wang JM, Segev DL, Werbel AWA| | PubMed
  5. Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients.
    Ou MT, Boyarsky BJ, Motter JD, Greenberg RS, Teles AT, Ruddy JA, Krach MR, Jain VS, Werbel WA, Avery RK, Massie AB, Segev DL, Garonzik-Wang JM| | PubMed
  6. Antibody Response to Severe Acute Respiratory Syndrome-Coronavirus-2 Messenger RNA Vaccines in Liver Transplant Recipients.
    Strauss AT, Hallett AM, Boyarsky BJ, Ou MT, Werbel WA, Avery RK, Tobian AAR, Massie AB, Hamilton JPA, Garonzik-Wang JM, Segev DL| | PubMed
  7. Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking Belatacept.
    Ou MT, Boyarsky BJ, Chiang TPY, Bae S, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, Garonzik-Wang JM| | PubMed
  8. SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in heart and lung transplant recipients.
    Hallett AM, Greenberg RS, Boyarsky BJ, Shah PD, Ou MT, Teles AT, Krach MR, Lรณpez JI, Werbel WA, Avery RK, Bae S, Tobian AA, Massie AB, Higgins RSD, Garonzik-Wang JM, Segev DL, Bush EL| | PubMed
  9. Antibody Response to the Janssen COVID-19 Vaccine in Solid Organ Transplant Recipients.
    Boyarsky BJ, Chiang TP, Ou MT, Werbel WA, Massie AB, Segev DL, Garonzik-Wang JM| | PubMed
  10. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.
    Werbel WA, Boyarsky BJ, Ou MT, Massie AB, Tobian AAR, Garonzik-Wang JM, Segev DL| | PubMed
19
View all 19 Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 19
  1. PASC in Solid Organ Transplant Recipients With Self-reported SARS-CoV-2 Infection.
    Alasfar S, Chiang TP, Snyder AJ, Ou MT, Boyarsky BJ, Abedon AT, Alejo JL, Cook S, Cochran W, Brigham E, Parker AM, Garonzik-Wang J, Massie AB, Brennan DC, Vannorsdall T, Segev DL, Avery RK| | PubMed
  2. Low-volume hospitals are not associated with inferior outcomes after thoracic endovascular aortic repair.
    Alhajri N, Yin K, Locham S, Ou M, Malas MB| | PubMed
  3. SARS-CoV-2 Messenger RNA Vaccine Immunogenicity in Solid Organ Transplant Recipients With Prior COVID-19.
    Boyarsky BJ, Barbur I, Chiang TP, Ou MT, Greenberg RS, Teles AT, Krach MR, Lรณpez JI, Garonzik-Wang JM, Avery RK, Massie AB, Segev DL, Werbel WA| | PubMed
  4. Antibody Kinetics and Durability in SARS-CoV-2 mRNA Vaccinated Solid Organ Transplant Recipients.
    Boyarsky BJ, Chiang TP, Teles AT, Greenberg RS, Krach MR, Ou MT, Massie AB, Tobian AAR, Garonzik-Wang JM, Segev DL, Werbel AWA| | PubMed
  5. Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients.
    Ou MT, Boyarsky BJ, Motter JD, Greenberg RS, Teles AT, Ruddy JA, Krach MR, Jain VS, Werbel WA, Avery RK, Massie AB, Segev DL, Garonzik-Wang JM| | PubMed
  6. Antibody Response to Severe Acute Respiratory Syndrome-Coronavirus-2 Messenger RNA Vaccines in Liver Transplant Recipients.
    Strauss AT, Hallett AM, Boyarsky BJ, Ou MT, Werbel WA, Avery RK, Tobian AAR, Massie AB, Hamilton JPA, Garonzik-Wang JM, Segev DL| | PubMed
  7. Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking Belatacept.
    Ou MT, Boyarsky BJ, Chiang TPY, Bae S, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, Garonzik-Wang JM| | PubMed
  8. SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in heart and lung transplant recipients.
    Hallett AM, Greenberg RS, Boyarsky BJ, Shah PD, Ou MT, Teles AT, Krach MR, Lรณpez JI, Werbel WA, Avery RK, Bae S, Tobian AA, Massie AB, Higgins RSD, Garonzik-Wang JM, Segev DL, Bush EL| | PubMed
  9. Antibody Response to the Janssen COVID-19 Vaccine in Solid Organ Transplant Recipients.
    Boyarsky BJ, Chiang TP, Ou MT, Werbel WA, Massie AB, Segev DL, Garonzik-Wang JM| | PubMed
  10. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.
    Werbel WA, Boyarsky BJ, Ou MT, Massie AB, Tobian AAR, Garonzik-Wang JM, Segev DL| | PubMed
  11. Kidney Transplant Recipient Attitudes Toward a SARS-CoV-2 Vaccine.
    Ou MT, Boyarsky BJ, Zeiser LB, Po-Yu Chiang T, Ruddy J, Van Pilsum Rasmussen SE, Martin J, St Clair Russell J, Durand CM, Avery RK, Werbel WA, Cooper M, Massie AB, Segev DL, Garonzik-Wang JM| | PubMed
  12. Early Development and Durability of SARS-CoV-2 Antibodies Among Solid Organ Transplant Recipients: A Pilot Study.
    Boyarsky BJ, Ou MT, Werbel WA, Avery RK, Clarke WA, Tobian AAR, Massie AB, Segev DL, Garonzik Wang JM| | PubMed
  13. Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients.
    Boyarsky BJ, Ou MT, Greenberg RS, Teles AT, Werbel WA, Avery RK, Massie AB, Segev DL, Garonzik-Wang JM| | PubMed
  14. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.
    Boyarsky BJ, Ruddy JA, Connolly CM, Ou MT, Werbel WA, Garonzik-Wang JM, Segev DL, Paik JJ| | PubMed
  15. Anemia as an independent predictor of adverse outcomes after carotid revascularization.
    Dakour-Aridi H, Ou MT, Locham S, Mathlouthi A, Farber A, Malas MB| | PubMed
  16. Measurement of Retinal Microvascular Blood Velocity Using Erythrocyte Mediated Velocimetry.
    Tracey BM, Mayo LN, Le CT, Chen VY, Weichsel J, Renner CY, Li J, Tsai JJ, Kalarn SP, Ou MT, Chang LY, Mohammed TK, Mohammed ISK, Shah KA, Thompson GM, Jones AMK, Im LT, Kaleem MA, Saeedi OJ| | PubMed
  17. Outcomes following Eversion versus Conventional Endarterectomy in the Vascular Quality Initiative Database.
    Dakour-Aridi H, Ou M, Locham S, AbuRahma A, Schneider JR, Malas M| | PubMed
  18. A Pilot Study on the Effects of Physician Gaze on Patient Satisfaction in the Setting of Electronic Health Records.
    Ou MT, Kleiman H, Kalarn S, Moradi A, Shukla S, Danielson M, Kaleem M, Boland M, Robin AL, Saeedi OJ| | PubMed
  19. Pathological ฮฑ-synuclein transmission initiated by binding lymphocyte-activation gene 3.
    Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, Ge P, Umanah GE, Brahmachari S, Shin JH, Kang HC, Zhang J, Xu J, Chen R, Park H, Andrabi SA, Kang SU, Gonรงalves RA, Liang Y, Zhang S, Qi C, Lam S, Keiler JA, Tyson J, Kim D, Panicker N, Yun SP, Workman CJ, Vignali DA, Dawson VL, Ko HS, Dawson TM| | PubMed